Travere Therapeutics Reports First Quarter 2022 Financial Results
05 mai 2022 16h01 HE
|
Travere Therapeutics, Inc.
Submitted New Drug Application (NDA) for sparsentan in IgA nephropathy in March 2022 Results from Phase 1/2 COMPOSE Study of pegtibatinase in classical homocystinuria (HCU) presented at the Society...
Travere Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
03 mai 2022 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the BofA...
Travere Therapeutics to Report First Quarter 2022 Financial Results
28 avr. 2022 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the close...
Travere Therapeutics Announces Plan for Chief Financial Officer Transition
20 avr. 2022 16h30 HE
|
Travere Therapeutics, Inc.
Laura Clague to step-down as CFO in August 2022 and retire in 2023 Chris Cline, Travere SVP of Investor Relations & Corporate Communications, to assume position of chief financial officer in...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 avr. 2022 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2022, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 43rd Annual Meeting and the Genetic Metabolic Dieticians International Conference 2022
06 avr. 2022 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present data from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase,...
Travere Therapeutics Submits New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
21 mars 2022 07h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 mars 2022 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, March 14, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2022, the Compensation Committee of its Board of Directors granted...
Travere Prices Upsized $275 Million Convertible Senior Notes Offering
08 mars 2022 21h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $275 million aggregate principal amount of 2.25%...
Travere Announces Proposed Convertible Senior Notes Offering
08 mars 2022 07h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $250 million aggregate...